NCT05071898RecruitingPhase 1
Pharmacogenetics of Response to GLP1R Agonists
Source: ClinicalTrials.gov · Last updated 27 Jul 2026
Brief summary (registry, in English)
Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests (FSIGT) both before and after semaglutide for six weeks. The proposal proposes two specific aims: 1. Specific Aim #1. To identify genetic variants associated with effects of a GLP1R agonist to enhance glucose-stimulated first phase insulin secretion in the two FSIGTs (before and after administration of drug). 2. Specific Aim #2. To identify genetic variants associated with the effect of a GLP1R agonist to accelerate the rate of glucose disappearance as assessed in the two FSIGTs (before and after administration of drug). Genotyping will be conducted using a high-density array with comprehensive coverage of DNA sequence variants. In addition, the analysis will leverage a global imputation panel generated from 1,025 Amish individuals.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- First submitted
- 27 Sept 2021
- Start date
- 11 Apr 2022
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- University of Maryland, Baltimore
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT05071898
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 600
- From 11 Apr 2022 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Unable to discontinue a drug, vitamin, or nutritional supplement, which in the judgment of the research physician or PIs might alter the response to semaglutide
Other illness
- Known allergy to semaglutide
- Personal or family history of medullary carcinoma of the thyroid or multiple endocrine neoplasia, type 2
Lab values
- History of diabetes (HbA1c \> 6.5% or random glucose \>200 mg/dL)
- eGFR \< 60 mL/min/1.73 sq. m.
- AST or ALT in excess of 2X the upper limit of normal
Age
- Woman of childbearing age who is sexually active
Other
- Medical issues, which in the judgment of the research physician or PIs might increase the risk associated with participation in the study
- Hematocrit \< 35%
- TSH \< 0.4 o4 \> 5.5
Who the study is looking for
- BMI greater than or equal to 27 kg/m2
- Of Amish Descent
Age in the registry: 18 years to 89 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amish Research Clinic Coordinator of this site? Confirm its status | Lancaster | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.